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Abstract
Shoc2 is a positive regulator of signaling to extracellular signal-regulated protein kinases 1 and 2 (ERK1/2). Shoc2 is also
proposed to interact with RAS and Raf-1 in order to accelerate ERK1/2 activity. To understand the mechanisms by which
Shoc2 regulates ERK1/2 activation by the epidermal growth factor receptor (EGFR), we dissected the role of Shoc2 structural
domains in binding to its signaling partners and its role in regulating ERK1/2 activity. Shoc2 is comprised of two main
domains: the 21 leucine rich repeats (LRRs) core and the N-terminal non-LRR domain. We demonstrated that the N-terminal
domain mediates Shoc2 binding to both M-Ras and Raf-1, while the C-terminal part of Shoc2 contains a late endosomal
targeting motif. We found that M-Ras binding to Shoc2 is independent of its GTPase activity. While overexpression of Shoc2
did not change kinetics of ERK1/2 activity, both the N-terminal and the LRR-core domain were able to rescue ERK1/2 activity
in cells depleted of Shoc2, suggesting that these Shoc2 domains are involved in modulating ERK1/2 activity.
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Introduction
Activation of mitogen-activated protein kinase/extracellular
stimulus-regulated kinase 1 and 2 (MAPK/ERK1/2) initiates a
complex network of signaling events that is regulated by scaffold
proteins [1–3]. These proteins determine specificity of signaling
outcomes by assembling unique signaling complexes at particular
subcellular localizations and controlling the information transfer
dynamics [4–6]. Scaffolds of the ERK1/2 signaling cascade tether
and target components of the multi-protein signaling modules to
various cellular locations (e.g. plasma membrane, endosomes,
Golgi), thus ensuring accessibility of specific substrates [7–11].
Changes in the stoichiometric ratio of scaffold proteins and their
binding partners may lead to titration of partner proteins into
separate complexes, thus inhibiting their interaction [12].
Due to their function as multivalent adaptor proteins, scaffolds
are often comprised of diverse structural and catalytic domains
that indicate potential functions and even putative partners of the
particular scaffold [13,14]. An example of the functional
complexity accomplished by the combination of multiple domains
is Kinase Suppressor of Ras 1(KSR1) [15,16]. KSR1 is a protein
that contains five conserved domains: among them are a proline-
rich sequence, a cysteine-rich domain that mediates interactions
with membrane lipids, a serine/threonine-rich region that binds
ERK/MAPK; and the putative kinase domain [8]. Other ERK1/
2 pathway scaffold proteins may not carry catalytic motifs, but do
have a number of protein interacting domains, including a
STERILE a-MOTIF (SAM), a PDZ domain, proline-rich Src-
homology-3 (SH3)-binding sites and a PH domain [8,17]. The
combination of domains composing the scaffold reflect the
function of the scaffold and the types of plausible interactors [4].
Shoc2 is a critical modulator of the ERK1/2 pathway and was
first identified in C. elegans (named SOC-2/SUR-8) [18–20]. Shoc2
forms a ternary complex with Ras and Raf-1 proteins [21],
thereby positively regulating Ras-mediated signaling [19]. More
recently, it was demonstrated that Shoc2 regulates ERK1/2
activity as a part of a holoenzyme comprised of Shoc2 and the
catalytic subunit of protein phosphatase 1c (PP1c) [22]. Shoc2 was
proposed to recruit PP1c to RAF-1 where PP1c dephosphorylates
an inhibitory serine residue allowing for subsequent activation of
RAF-1. Moreover, it was shown that Shoc2 modulates Ras-
dependent Raf-1 activation in a Ca(2+)- and calmodulin-depen-
dent manner [23,24] in addition to reserving Ras-GTP for Raf-1,
accelerating Ras-GTP binding to Raf-1, and enabling rapid
temporal response to EGFR stimulation. Another study found that
the S2G mutation of Shoc2 causes Noonan-like syndrome by
promoting aberrant protein N-myristoylation and results in Shoc2
plasma membrane targeting [25]. A Shoc2 mouse knockout
revealed that Shoc2 is essential for embryonic heart development
[26]. We recently reported that Shoc2 translocates from the
cytosol to late endosomes upon EGFR activation, while translo-
cation of the S2G mutant of Shoc2 to late endosomes is impaired
[27].
The basis for the Shoc2 function in accelerating ERK1/2
activity is unclear since it has only one recognized sequence – the
leucine-rich repeats (LRR) domain and does not have a modular
organization of other scaffold proteins. LRR proteins form a large
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family of intracellular, extracellular, and membrane-attached
mostly eukaryotic proteins with cellular functions ranging from
immune response and signal transduction to cell adhesion, RNA
splicing and synapse development and functioning [28–32].
Despite their functional diversity, it is proposed that most LRR
proteins participate in some form of protein-protein interactions
and share a common, ‘‘solenoid’’-like structure, with each LRR
being a turn of the solenoid. Unique homogeneous structure of
Shoc2 without obvious catalytic motifs or other interacting
domains makes studies of Shoc2 particularly challenging. There-
fore, to further our understanding of how Shoc2 regulates ERK1/
2 signaling, we designed a structure-function study addressing the
significance of particular Shoc2 regions for Shoc2 function and its
cellular localization. We determined that an N-terminal domain,
located prior to the LRR domain of Shoc2, contains an M- Ras-
binding motif, while Shoc2 segment responsible for Shoc2
targeting to late endosomes is located at the C-terminus of Shoc2.
We observed that M-Ras mediates interaction of Raf-1with Shoc2.
Binding of Shoc2 with M-Ras is independent of the ERK1/2
pathway activation and M-Ras GTPase activity. Using a
combination of shRNA and Shoc2 rescue approaches, we
demonstrate that both, the N-terminal and the LRR domains
are supporting the Shoc2 function in controlling ERK1/2 activity.
Results
Defining the LRRs in Shoc2
First, to determine the contribution of the individual structural
components of Shoc2 to its function as a positive modulator of
ERK1/2 activity, we defined the LRR boundaries. Although
Shoc2 homologues in several organisms have been identified
earlier [19], we have extended the sequence analysis using profile
based sequence comparison to achieve a maximal resolution in
sequence evaluation. Multiple Shoc2 orthologues in five classes of
vertebrates (mammalia, aves, amphibia, reptilia and actinopter-
ygii) were readily recognized by the National Center for
Biotechnology Information’s (NCBI) BLASTp analysis using
human Shoc2 as the index sequence. In addition, we identified
Shoc2 orthologues in several widely disparate group of organisms
including cyanobacteria, plasmodium, parasitic trematode, nem-
atode, plants (rice and arabidopsis), and insects (fruit fly, yellow
fever mosquito, and honey bee) (Supporting Information 1).
Although, most of the Shoc2 vertebrate orthologues were very
consistent in size and contained approximately 580 amino acids,
its other orthologues varied in size from 309 to 1009 amino acids.
To ensure that we had identified Shoc2 orthologues and to
determine their percent of similarity and identity to H. sapiens
Shoc2, we used the GeneiousTM software package and generated
pairwise alignments of 22 proteins. The similarities ranged from
51% for the plasmodium orthologue of Shoc2 to 100% for primate
orthologues (Figure 1A). In addition to the LRR domain, we found
that the N-terminal domain of Shoc2 was highly conserved in
amino acid composition and length (85 amino acids) among
mammalia, aves, reptilia and amphibia (e.g. 64.7% identity
between human and frog) (Figure 1A and Figure S1).
Secondary structure prediction and multiple alignment analysis
showed that the number of LRRs in Shoc2 is 21 (23 to 24 amino
acids in length) in mammals (Figure 1B), amphibians, reptiles,
actinopterygii and drosophila; 18 in aves; and variable numbers in
plant orthologues. The repeats of all Shoc2 orthologues contain a
highly conserved consensus, PxxIxxLxxLxxLxLxxNxLxxL, and
encompass a consensus that is typically present in other LRR
proteins, LxxLxLxxNxL (x being any amino acid) (Figure 1C).
Notably, sequence conservation in the secondary structure (b-
strands) was rather remarkable and aligned well with typical
secondary structure of LRR proteins [33,34], suggesting that these
sequences may be involved in conserved interactive functions.
LRR structures are often flanked by N-terminal (LRRNT) and
C-terminal (LRRCT) capping motifs that protect the hydrophobic
core of the first and the last LRRs. This consensus sequence
usually contains four cysteines in a CxnCxCxmC pattern, with n
and m being variable numbers [35,36]. We could not identify
typical LRRNT or LRRCT motifs within Shoc2. However, we
found that the N- and C-terminal LRRs (amino acids 92 to 115
and 558 to 580) showed lower similarity to the other ‘‘true’’ LRR
sequences and probably serve capping functions, often observed in
LRR domains and essential for stabilizing the fold of the protein.
Indeed, the protein half-life of the Shoc2 truncated mutants
lacking the N-terminal domain and the first LRR (aa116–582) is
significantly shorter (,2 hours) than that of the full-length Shoc2
(,24 hours) (Figure S2B). Interestingly, with the exclusion of the
N- and C-capping repeats, the percentage of identity in ‘‘true’’
LRR regions ranged from 54.8% for a parasitic trematode
orthologue of Shoc2 to 100% for primate orthologues, which was
significantly higher than the similarity/identity range for the full-
length Shoc2 orthologues.
Utilizing homology and threading based modeling, a molecular
model of the full LRR domain of Shoc2 was constructed
(Figure 1D). The model clearly supported the 21 repeats in the
Shoc2 LRR domain and not 18 LRRs, as was previously suggested
[19]. This model of the LRR domain architecture was utilized in
our subsequent engineering of Shoc2 truncation mutants. Taken
together, these data indicated that the mammalian Shoc2 contains
a conserved 21-repeat LRR domain. This data also suggested that
the N-terminal domain may represent a distinct domain that is
significant for Shoc2 function.
Localization of Shoc2 truncated mutants
To define the structural elements critical for Shoc2 function as a
positive regulator of the ERK1/2 pathway and to determine
which part of molecule confers the delivery of Shoc2 to
endosomes, we prepared several truncated versions of monomeric
tag red fluorescent protein (tRFP)-tagged Shoc2 starting with
separating the LRR region from the non-LRR N-terminus
(Figure 2A). Truncations were expressed in Cos-LV1 cells depleted
of endogenous Shoc2 [27]. Analysis of the subcellular localization
of Shoc2-tRFP truncated mutants using live-cell fluorescence
microscopy demonstrated that the N-terminal domain (aa1-115)
was found in cytosol and in the nucleus in Cos-LV1 cells before or
after stimulation with EGF (Figure 2B). Cytosolic/nuclear
localization of the N-terminal domain was confirmed by subcel-
lular fractionation (Figure 2B). The LRR-domain of Shoc2-tRFP
(aa81–560) was found mostly in cytosol. Surprisingly, the Shoc2
truncated mutant that spans the two C-terminal LRRs (aa532–
582) when expressed in Cos-LV1 cells was found in vesicular
structures before or after stimulation with of EGF. These vesicles
appeared as fluorescent dots or as donut-like structures with
occasionally visible limiting membrane (Figure 2B). The majority
of the vesicles showed rapid lateral and directed movement over
long distances, while others were relatively static (Movie S1).
These vesicular structures localized to the Rab7-positive endo-
somes but did not co-localize with Rab5-positive endosomes in
living cells (Figure 2C). The localization of this fragment to Rab7-
positive endosomes was particularly easy to detect on a fused
Rab7-positive compartment, presumably due to overexpression of
CFP-Rab7. These data suggested that LRRs 20–21 at the C-
terminus of Shoc2 contain sequences responsible for targeting of
Shoc2 Structure-Function
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Shoc2 to Rab7 positive late endosomes, and other regions may
structurally hinder these sequences.
Identification of the binding regions for the immediate
protein partners – M-Ras and RAF-1
To understand a role the Shoc29s domains play in its function as
a positive regulator of ERK1/2 signaling we mapped regions that
are responsible for the direct binding to its immediate signaling
partners Ras and Raf-1. Given that ablation of Shoc2 in mice led
to embryonic lethality due to severe heart defects, we performed a
yeast two-hybrid screen using a human ventricle and embryo heart
library and full-length Shoc2 as bait. Twenty-tree positive clones
encoding to M-Ras cDNA (aa1-199) and no other Ras isoforms
(e.g. K-Ras, H-Ras or N-Ras) were identified during this screen.
Thus, in the following experiments we have used an M-Ras
isoform to define structural elements of Shoc2 that are essential for
the M-Ras binding.
In our initial experiments we tested the Shoc2 – M-Ras and -
Raf-1 interaction using Shoc2 tagged with tRFP fluorescent
protein (Shoc2-tRFP) and YFP-tagged M-Ras or Raf-1 co-
expressed in 293FT cells (Figure 3A). YFP-Raf-1 immunoprecip-
itated Shoc2-tRFP (lane 1), but failed to precipitate endogenous
Shoc2 (lane 3), possibly due to changes in the stoichiometric ratio
of the components of the Shoc2 complex. Stimulating cells with
2ng/ml of EGF had a little effect on Shoc2-Raf-1 binding (lanes 6
and 7), suggesting that while Shoc2 is in complex with Raf-1 the
activation of the ERK1/2 pathway does not lead to the
recruitment of Raf-1 to Shoc2. Conversely, YFP-M-Ras was
capable of efficiently precipitating both Shoc2-tRFP (lane 2) and
endogenous Shoc2 (lane 4) even under the condition of serum
Figure 1. Defining the LRRs of Shoc2. A, Protein sequences from twenty two Shoc2 orthologues were utilized to generate an alignment of full-
length Shoc2. The alignment was use to define the percent of similarity and identity of each Shoc2 orthologue to human Shoc2. B, Protein sequences
from ten Shoc2 vertebrate orthologues were utilized to generate an alignment of the N-terminal domain. The alignment was use to define the
percent of identity of each Shoc2 orthologue to human Shoc2. C, Schematic representation of Shoc2 LRR and non-LRR regions. D,Multiple alignment
of the individual twenty one LRRs of human Shoc2. The motif includes conserved sequence positions for the LRRs. Residue conservation color
scheme: residues boxed in black are identical, and those boxed is dark and light grey are conserved substitutions. E, Ribbon representation of the
model structure of Shoc2. Three structure elements characterize the fold of this protein: tandemly repeating units – LRRs, the b sheets that occupy
the concave face of the scaffold and a regular array of possible helixes that characterizes its convex face.
doi:10.1371/journal.pone.0066067.g001
Shoc2 Structure-Function
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starvation, though these results were somewhat in contrast to what
was previously reported for the Shoc2 binding of M-Ras and Raf-1
[22]. To further explore this discrepancy, we performed co-
transfection experiments to compare binding of GTP-bound and
GDT-bound M-Ras proteins to Shoc2. Results in Figures 3B and
C show that both mutants of HA-tagged M-Ras, GTP-bound
(G22V) and GDP-bound (S27N) [37], maintained their capacity to
precipitate Shoc2, suggesting that Shoc2-M-Ras binding is
independent of GTPase activity of M-Ras.
To define the M-Ras binding region more closely, we prepared
a series of truncated mutants of Shoc2-tRFP (Figure 4A). All
mutants represented in this study are stable and have a half-life
similar to full-length Shoc2 (Figure S2B). 293FT cells were
transiently co-transfected with HA-M-Ras and generated Shoc2-
tRFP constructs and the capacity of HA-M-Ras to bind Shoc2-
Figure 2. Localization of Shoc2 truncated mutants in Cos-LV1 cells. A, Cos-LV1 cells were transfected with Shoc2-tRFP truncated fragments
and imaged live before and after EGF treatment (0.2ng/ml, 15 min at 37uC). Shoc2-tRFP was located in the cytosol and nucleus. Scale bar, 10 mm. B,
Cos-LV1 cells were transfected with full-length Shoc2-tRFP and its truncated fragments, and subjected to the cell fractionation. Cell lysates were
immunoblotted (IB) with tRFP Abs to monitor expression of Shoc2, and p84 (nuclear fraction-N) Abs and GAPDH (cytosolic faction-C) to control for
the purity of fractions. 30 mg of total lysate for each fraction was loaded for IB analysis. Results in each panel are representative of three independent
experiments. C, Shoc2-tRFP mutant (532–582aa), CFP-Rab7 and CFP-Rab5 were transiently expressed in Cos-LV1 cells. Cells were serum-starved for
16h and then treated as in A. Insets show high magnification images of the regions of the cell indicated by white rectangles, Scale bar, 10 mm.
doi:10.1371/journal.pone.0066067.g002
Shoc2 Structure-Function
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tRFP was tested (Figure 4B). Surprisingly, only the full-length
Shoc2 and the mutants containing the N-terminal domain of
Shoc2 co-precipitated with HA-M-Ras (lanes 1–4). Shoc2
fragments lacking the N-terminal domain failed to co-precipitate
with HA-M-Ras (lanes 5–8). We observed that amounts of the N-
terminal fragments in precipitates were higher than that of other
Shoc2 mutants suggesting that the detected interaction of the N-
terminal domain of Shoc2 with HA-M-Ras is not just due to the
protein overexpression in cells. This also indicated that the N-
terminal domain of Shoc2 is essential and sufficient for the
association of Shoc2 with M-Ras.
The previous studies have identified loss of function mutations
(D175N, C260Y, E457D and P510L) in C. elegans homologue of
Shoc2, SUR8 [19]. Two of these point mutations (D175N and
E457D) have been reported to disrupt M-Ras binding to Shoc2
[22]. As shown in Figure 4C, corresponding mutations in the
Shoc2-tRFP sequence had no effect on the Shoc2-tRFP-HA-M-
Ras binding, supporting our findings that the Shoc2 and M-Ras
interaction is mediated by the N-terminal domain of Shoc2.
Given that Shoc2 was previously reported to interact with both
Ras and Raf-1 proteins, we next ascertained the nature of Shoc2
and Raf-1 binding and determined a region that mediates Shoc2
association with Raf-1. To that end, 293FT cells were transiently
transfected with the Shoc2-tRFP truncated mutants (Figure 5A
and Figure S3A), GST-Raf-1, and HA-M-Ras and GST-Raf-1
was used to precipitate Shoc2 (Figure 5B). As expected, the
interaction of the full length Shoc2-tRFP with Raf-1was much
weaker (lane1) than it’s interaction with HA-M-Ras (lane 10).
Mutants containing the N-terminal domain of Shoc2 readily
precipitated with GST-Raf-1 (lanes 2 and 3), while the Shoc2-
tRFP truncations lacking the N-terminal domain failed to co-
precipitate with GST-Raf-1(lanes 4 and 5). Moreover, GST-Raf-1
precipitated the N-terminal M-Ras binding domain (aa1-115,
lane2) surprisingly well (Figure S3B). Thus, we next tested whether
the N-terminal domain of Shoc2 will compete for Shoc2
interaction with Raf-1 or M-Ras. Cells expressing GST-Raf-1
(lane 6) or HA-M-Ras (lane 7) were transfected with both Shoc2-
tRFP and the N-terminal domain of Shoc2 (aa1-115). We
observed reduced binding of the full-length Shoc2-tRFP to HA-
M-Ras (lane 10 vs. lane 7) and GST-Raf-1 (lane 1 vs. lane 6).
These data suggested that the N-terminal domain of Shoc2
sequestered M-Ras in cells and implied that the interaction of
Shoc2 with Raf-1 is mediated by M-Ras, presumably through its
Raf-1binding domain.
Functional status of Shoc2 truncated mutants
To further analyze the role of the Shoc29s domains in regulating
ERK1/2 signaling initiated by EGFR, we generated Cos1 cells
(LV-SR) that have endogenous Shoc2 replaced with Shoc2-tRFP.
In these cells endogenous Shoc2 was stably silenced by shRNA
and replaced by ectopically expressed Shoc2-tRFP. In Shoc2-
tRFP 6 ‘‘silent’’ mutations were introduced to generate it to be
resistance to shRNA without changing its amino acid sequence
[27]. The control cells expressing either non-targeting shRNA
(LV-NT) or Shoc2 specific shRNA only (LV1) have been
developed and reported previously, and have been used in the
Figure 3. Shoc2 interaction with M-Ras and Raf-1. A, 293FT cells transiently co-transfected with expression vectors encoding full-length Shoc2-
tRFP, YFP-Raf-1 or YFP-M-RAS. Twenty-four hours post-transfection, cells were starved for 16 hours, stimulated with EGF (2 ng/ml) for 15min and
lysed. YFP-Raf-1 or YPF-M-Ras were immunoprecipitated (IP) using GFP antibody, and the immunoprecipitates were probed by immuno-blotting (IB)
with Shoc2 and, subsequently, with GFP- and M-Ras antibodies to detect Raf-1 and Ras. Cell lysates were first immunoblotted with anti-Shoc2
antibodies to monitor Shoc2 expression, and then immunoblotted with anti-Raf-1 antibodies to monitor expression of YFP-Raf-1 and M-Ras antibody
to monitor expression of YFP-M-Ras proteins. * denotes a proteolytic fragment of Shoc2-tRFP that is often detected by IB in cells expressing full-
length Shoc2-tRFP. Shoc2-tRFP signal that is visible on the Raf-1 blot is indicated. B. 293FT cells transiently expressing HA-M-Ras and HA-M-Ras
mutants (S27N and G22V). Thirty-six hours post-transfection, cells were lysed. M-Ras was immunoprecipitated using HA antibody, and the
immunoprecipitates were probed by IB with Shoc2 and, subsequently, with HA-antibodies to detect Raf-1 and Ras. Cell lysates were immunoblotted
with anti-HA antibody to monitor expression of corresponding M-Ras mutants used in panel IP or Shoc2 Abs to monitor expression of endogenous
Shoc2. C. Cos-SR cells transiently expressing HA-M-Ras and its mutants were subjected to IP as in B. M-Ras was immunoprecipitated using HA
antibody, and the immunoprecipitates were probed by IB with Shoc2 and, subsequently, with HA-antibodies to detect M-Ras. Cell lysates were
immunoblotted with anti-HA antibody to monitor expression of corresponding M-Ras mutants used in panel IP or tRFP Abs to monitor expression of
Shoc2-tRFP. Results in each panel are representative of three independent experiments.
doi:10.1371/journal.pone.0066067.g003
Shoc2 Structure-Function
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following experiments of this study. The effect of Shoc2
knockdown on the ERK1/2 pathway activation was most evident
when the cells were stimulated with low, physiological (0.2 ng/ml)
concentration of EGF [27], thus in following experiments cells
were stimulated with the corresponding concentration of EGF.
LV-SR cells were next utilized to assess whether overexpression of
Shoc2 affects the amplitude or the duration of ERK1/2 activity.
In order to prevent clonal variations due to the different sites of
viral genome incorporation in our experiments we used a pool
population of LV-SR cells, constitutively expressing Shoc2 shRNA
and Shoc2-tRFP. Data presented in Figure 6 show that Cos1 and
LV-SR cells had comparable amplitude and duration of ERK1/2
activation when stimulated with low concentration of EGF
(0.2 ng/ml) for a maximum period of 120 min. These data also
demonstrated that Shoc2-tRFP is capable of fully rescuing EGF-
induced ERK1/2 phosphorylation when expressed constitutively,
and an increase in Shoc2-tRFP levels in cells does not affect the
kinetics of ERK1/2 signals.
Previous studies showed that overexpression of scaffold proteins
followed by changes in stoichiometry of the complex components
may lead to an increase or inhibition of the ERK1/2 pathway
activity [10]. As the Shoc2 signaling partners M-Ras and Raf-1
interact with the N-terminal domain of Shoc2, we reasoned that
the mechanism underlying the ability of Shoc2 to accelerate
activation of the ERK1/2 pathway may be supported by this
region of Shoc2. Thus, we next tested whether expression of the
Shoc2-tRFP truncated mutants will affect activation of the ERK1/
2 pathway in the presence of endogenous Shoc2 (Figure 7A and
Figure S4). Shoc2 antibodies recognize an epitope on the N-
terminus of Shoc2, thus to simultaneously detect expression of
endogenous Shoc2 and all the Shoc2-tRFP truncated mutants
utilized in this study we first probed our western blots with Shoc2
and then with tRFP antibody. All Shoc2-tRFP constructs had 6
‘‘silent’’ mutations introduced to render them resistant to shRNA
without changing the amino acid sequence, as reported earlier
[27]. Surprisingly, expression of Shoc2-tRFP truncated mutants in
Cos1 cells stimulated with low (0.2 ng/ml) concentration of EGF
had no significant effect on ERK1/2 activation (Figure 7B). At the
expression levels that were maximally achievable for the reported
constructs in Cos1 cells, only a minimal increase in ERK1/2
phosphorylation (by factor of 0.5) was observed (Figure 7B).
Expression of the N-terminal domain of Shoc2 (lane 6) and the
truncated mutant that contains a late-endosomal targeting region
(lane 7) also resulted in only a moderate increase in ERK1/2
phosphorylation.
To test the capacity of Shoc29s domains to rescue the ERK1/2
pathway activation, different Shoc2-tRFP truncated mutants were
expressed in Cos-LV1 cells stimulated with 0.2 ng/ml of EGF
(Figure 8A).Transient expression of the full-length Shoc2-tRFP in
Cos-LV1 cells fully rescued ERK1/2 activation (by a factor of 3.5
to 4.5) (lane 4). The ERK1/2 phosphorylation signal in cells
transiently expressing Shoc2-tRFP was slightly lower than in Cos1
or LV-NT cells, presumably, due to the fact that not all Cos-LV1
cells expressed Shoc2-tRFP. Expression of the N-terminal domain
of Shoc2 in Cos-LV1 cells led to a partial recovery of ERK1/2
phosphorylation (by a factor of 1.5 to 2) (lanes 5 and 6).
Unexpectedly, expression of other Shoc2 truncated mutants,
including the truncations containing the endosomal targeting
signal (lane 8), also restored ERK1/2 activity above the basal level
of EGF-induced ERK1/2 activity in Shoc2-depleted cells
(Figure 8B). These data indicate that multiple Shoc2 domains,
including its N-terminus, LRR-core and endosomal targeting
domain play a role in Shoc2 function as a positive modulator of
ERK1/2 signaling.
Figure 4. Shoc2 binding of M-Ras in 293FT cells. A. Schematic representation of the full-length and truncated Shoc2-tRFP constructs. B, 293FT
cells were transiently co-transfected with full-length or truncated tRFP-tagged Shoc2 and 3xHA-M-RAS. Thirty-six hours post-transfection, cells were
lysed and lysates were subjected to immunoprecipitation (IP) with HA antibody. The IP fraction was analyzed by immuno-blotting (IB) with tRFP and,
subsequently, with HA-antibodies to detect Shoc2 and Ras. Cell lysates were immunoblotted with anti-HA antibody to monitor expression of Ras
proteins or tRFP Abs to monitor expression of full-length Shoc2 and corresponding truncated mutants used in panel IP. Dotted line shows area of the
blot that was cropped to minimize occupied space. C. 293FT cells were transiently co-transfected with expression vectors encoding full-length or
mutated tRFP-tagged Shoc2 and 3xHA-M-RAS. Thirty-six hours post-transfection, cells were lysed. Lysates were subjected to IP with anti-HA antibody
as described in B. Results in each panel are representative of three independent experiments.
doi:10.1371/journal.pone.0066067.g004
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In summary, our data demonstrate that, in addition to its LRR-
core, the Shoc29s N-terminal domain and its C-terminal endosome
targeting region are the part of the mechanism that regulates
ERK1/2 pathway activity induced by EGFR activation.
Discussion
The ERK1/2 pathway scaffold protein Shoc2 belongs to a
family of the LRR proteins that shares a common structural
framework with repeats arranged to form a continuous super-helix
[38]. This structure appears to be the principal reason that most of
the LRR proteins are involved in protein-protein interactions
[34,39]. We explored and analyzed Shoc2 structural properties to
elucidate the mechanisms underlying Shoc29s function as a
modulator of ERK1/2 signaling and Shoc2 distribution in cells.
As bioinformatic analysis demonstrates, Shoc2 is broadly
distributed and highly conserved not only in vertebrates but also
in many disparate taxa, with strikingly high levels of sequence
similarity in its LRR domain (Figure 1A). Additionally, we found
that the non-LRR N-terminal domain of Shoc2 is highly
conserved in vertebrates, suggesting that the N-terminal domain
represents a previously overlooked functionally important domain.
These findings also indicate that both regions of Shoc2 (N-
terminus and LRR core) retained their function during the course
of evolution. Sequence differences in the N-terminus of Shoc2
between vertebrate and invertebrate orthologues may reflect
diversion in function and/or variation in binding partners with
the possibility of Shoc2 orthologues supporting distinct but related
functions.
Molecular modeling and sequence analysis showed that the
Shoc2 solenoid is built of 21 LRRs with each LRR containing the
amino acid sequence LxxLxLxxN/CxL (x being any amino acid).
The first and the last of the 21 LRRs are likely acting as capping
repeats and stabilize the Shoc2 fold. This conclusion is also
consistent with earlier demonstrations that LRRs of other proteins
often have a significant degree of structural complementarity with
their immediate neighboring repeats or capping structures
covering them, and engineering truncated LRR domains with
poor complementarity destabilizes them [28,40].
In an effort to identify domains responsible for the spatial
distribution of Shoc2, we found that the N-terminal truncated
mutant of Shoc2 is localized in the cell nuclei regardless of the
activation status of the ERK1/2 pathway (Figure 2). Further
studies will explore whether this nuclear localization of Shoc2 is
the result of Shoc2 overexpression, or a part of Shoc29s trafficking
route controlled by the mechanisms of nuclear import/export. We
also found that the C-terminal fragment of Shoc2 (aa532–582),
when isolated from the rest of the solenoid and tagged with tRFP,
was targeted to the surface of late endosomes. It is tempting to
speculate that the last two LRRs contain a novel recognition motif
responsible for the Shoc2 delivery to endosomes. Since Shoc2
lacks any trans-membrane segments, this motif will likely associate
with a protein and/or lipids at the periphery of the late endosome
membrane. We previously demonstrated that full-length Shoc2 is
delivered to late endosomes upon activation of the ERK1/2
pathway and suggested that the mechanism that governs targeting
of Shoc2 to late endosomes requires greater temporal control.
Thus, the newly identified endosome-binding interface of Shoc2
could be a part of such a mechanism directing dynamic changes in
Shoc2 distribution. Future studies will unravel mechanisms and
sequences/motif that are responsible for Shoc2 targeting to late
endosomes.
Interaction of Shoc2 with Raf-1 and different members of Ras
family have been reported in several conflicting studies [19,20,22].
Our yeast two-hybrid screen of human heart library with Shoc2 as
a bait had recognized isolates of only one Ras isoform, M-Ras.
Given that M-Ras is highly expressed in heart [37] and that Shoc2
knock-out mice exhibit major heart defects [26], it is possible that
Shoc2-Ras complexes are tissue specific and M-Ras is a preferable
Shoc2 partner in heart tissues. To our surprise, the immunopre-
cipitation experiments showed that the N-terminal domain of
Shoc2 provides a binding surface to M-Ras (Figure 3 and 4).
Although, previous reports by Li, et al. (2000) and Sieburth, et al.
(1998) showed that deletion of the C-terminal 53 amino acids or
even several C-terminal LRRs of the C. elegans orthologue of Shoc2
eliminated LET-60 Ras binding, we have not found the C-
terminal region of human Shoc2 to be necessary for the binding of
M-Ras (Figure 3). Moreover, binding of M-Ras to Shoc2 was
independent of ERK1/2 pathway activation and the GTPase
activity of M-Ras. Therefore, it is possible that in addition to
having a preferred Ras partner in specific tissues, Shoc2 also uses
Figure 5. Shoc2 binding of Raf-1 in 293FT cells. A. Schematic
representation of the full-length and truncated Shoc2-tRFP constructs.
B. 293FT cells were transiently co-transfected with expression vectors
encoding full-length or truncated tagRFP-tagged Shoc2 and YFP-Raf-1
or YFP-M-RAS. Thirty-six hours post-transfection, cells were lysed. GST-
Raf-1 was precipitated with glutathione-coupled beads. HA-M-Ras was
immuno-precipitated (IP) with HA antibody. The precipitated fraction
was analyzed by immuno-blotting (IB) with tRFP and subsequently with
Raf-1 and HA-antibodies to detect Raf-1 and Ras. Cell lysates were
immunoblotted with Raf-1 antibodies to monitor expression of GST-Raf-
1, HA antibodies to monitor expression of HA-M-Ras proteins, and tRFP
antibodies to monitor expression of Shoc2 and its corresponding
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discrete mechanisms to bind specifically different members of the
Ras family (e.g. H-Ras, K-Ras, N-Ras), and further studies will
define molecular determinants dictating this specificity. Our results
also provide evidence that M-Ras mediates Raf-1 proximity with
Shoc2 (Figure 3), which agrees with studies by Rodriguez-Viciana,
et al. (2006) showing that Raf-1 does not interact directly with
Shoc2.
Based on the results that the LRR domain is not engaged in M-
Ras-Raf-1- binding, we suggest that the LRR domain is available
to bind other partners of this scaffold complex or, perhaps,
available to form stable dimers. It also indicates that mechanisms
of Shoc2 function are more complex than a simple tethering of the
Ras and Raf-1. These data coincide with a Shoc2 accelerator
model proposed in the study by Matsunaga-Udagawa, R. et al. in
which Shoc2 accelerated both the association and the dissociation
of the Ras-RAF-1 interaction [23].
Another important finding was that in cells activated with the
low, physiological concentrations of EGF overexpression of Shoc2-
tRFP had no effect on activation of ERK1/2 in the presence of
endogenous Shoc2 (Figures 7 and 8), though it was in contrast to
what was observed in other studies when EGFR was activated
using high EGF concentrations [25]. Outcomes of our experi-
ments are reminiscent to what was observed in overexpression
studies of other ERK1/2 scaffold proteins, KSR1and MP1/p14.
Full-length KSR1 when expressed at high levels blocked ERK1/2
activation and the KSR-mediated R7 photoreceptor formation
[41–44]. Overexpressed p14, a partner in the MP1/p14 scaffold-
ing complex, did not have an effect on ERK1/2 signaling and
could only significantly stimulate ERK1 activity in vitro, when
stoichiometry of signaling complexes was not disrupted [45,46].
MP1 expressed at various concentrations affected assembly of the
MP1-MEK1-ERK1 signaling modules and ERK1/2 activity by
either inhibiting or stimulating ERK1/2 signaling, again, relative
to the stoichiometry of the complex components [47,48]. Notably,
our recovery studies revealed a role for both, the N-terminal and
the LRR Shoc2 domains, in regulating EGFR-mediated activation
of the ERK1/2 pathway. The N-terminal domain supports Ras-
Raf-1 complex assembly, thus it was expected that this domain
would rescue ERK1/2 activity. On the other hand, we did not
expect to find that expression of other truncated mutants would
accelerate ERK1/2 activity in Cos-LV1 cells (Figure 8). Further-
more, we did not expect to find that the rescue effects of the Shoc2
isolated domain on ERK1/2 activation did not vary with the levels
of expressed protein. An attractive explanation for these observa-
Figure 6. Overexpression of Shoc2 does not affect ERK1/2 activation by EGF in Cos1 cells. A, Parental Cos1 and Cos1 cells stably
expressing Shoc2-shRNA (Cos-LV1) or Shoc2-shRNA and Shoc2-tRFP (LV-SR) were serum-starved up to 12 hours and treated with 0.2ng/ml EGF for
indicated times at 370C. The lysates were probed for Shoc2, activated ERK1/2 (pERK1/2), total ERK1/2 (ERK1/2) and GAPDH (loading control). Results
in each panel are representative of three independent experiments. * denotes a proteolytic fragment of Shoc2-tRFP that is detected by immuno-
blotting (IB) in cells expressing full-length Shoc2-tRFP. B, Multiple blots from the experiments exemplified in A were analyzed.
doi:10.1371/journal.pone.0066067.g006
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tions would be that the Shoc2 domains combine two separate
functionalities that exert both positive and negative effects on
ERK1/2 signaling. When taken out of context of the full-length
molecule, the Shoc2 N-terminal domain assembles Ras-Raf-1
complexes and rescues ERK1/2 activity. As for the LRR core, its
expression will dilute other Shoc2 binding partners that negatively
affect ERK1/2 activity. This model is consistent with that
proposed by Matsuda and co-workers that implies a negative
feed-back loop involving Shoc2 [24]. One possible partner is PP1c,
as Shoc2 is a part of the PP1c holoenzyme [22]. However titration
of PP1c alone cannot account for such an increase in ERK1/2
phosphorylation observed in rescue experiments.
Therefore, we propose that the function of Shoc2 goes beyond
its role in tethering of Ras-Raf-1 and enforcing their physical
proximity, but Shoc29s function extends to the coordinating and
integrating positive and negative ERK1/2 feedback loops. The
LRR domain is the one that is most likely to govern the negative
feedback loop. Further biochemical studies will assess the precise
architecture of the complex formed by Shoc2 through LRR,
determine the mechanisms coupling both feedback loops, and




EGF was obtained from BD Bioscience (Bedford, MA).
Antibodies to EGFR, RAF-1, ERK1/2, phospho-ERK1/2, M-
Ras, and GAPDH were from Cell Signaling Technology; Shoc2
and GFP antibodies were from Abcam (USA); HA antibodies were
from SydLabs; tRFP antibodies from Invitrogen, p84 antibodies
were from GeneTex (Irvine, CA). Pfu polymerase was purchased
from Stratagene (La Jolla, CA).
Figure 7. Wild-type Shoc2 and Shoc2 truncated mutants do not
have a dominant-interfering effect in Cos-NT cells A, Cos1 cells
were transiently transfected with full-length Shoc2-tRFP or Shoc2-tRFP
truncated mutants. Cells were serum-starved for up to 12 hours and
treated with 0.2 ng/ml EGF for indicated times at 37uC. The lysates were
probed by immuno-blotting (IB) for Shoc2, tRFP, activated ERK1/2
(pERK1/2), total ERK1/2 (tERK1/2) and GAPDH (loading control). Dotted
line shows area of the blot that was cropped to minimize occupied
space. * denotes a proteolytic fragment of Shoc2-tRFP that is detected
by immuno-blotting (IB) in cells expressing full-length Shoc2-tRFP. B,
Multiple blots from the experiments exemplified in A were analyzed.
Bars represent the mean values (6S.E., n=4) of phosphorylated ERK1/2
activity normalized to total ERK1/2 in arbitrary units (pERK1/2/ERK),
P = 0.938 (one-way ANOVA test was used to determine differences in
phosphorylated ERK1/2 activity).
doi:10.1371/journal.pone.0066067.g007
Figure 8. Wild-type Shoc2 and Shoc2 truncated mutants
rescues Shoc2 knockdown. A, Cos-LV1 cells were transiently
transfected with full-length Shoc2-tRFP or Shoc2-tRFP truncated
mutants. Cells were serum-starved for up to 12 hours and treated with
0.2ng/ml EGF for indicated times at 37uC. The lysates were probed by
immuno-blotting (IB) for Shoc2, tRFP, activated ERK1/2 (pERK1/2), total
ERK1/2 (tERK1/2) and GAPDH (loading control). Dotted line shows area
of the blot that was cropped to minimize occupied space. * denotes a
proteolytic fragment of Shoc2-tRFP that is detected by IB in cells
expressing full-length Shoc2-tRFP. B, Multiple blots from the experi-
ments exemplified in A were analyzed. Bars represent the mean values
(6S.E., n=3) of phosphorylated ERK1/2 activity normalized to total
ERK1/2 in arbitrary units (pERK/ERK), a vs. b, P,0.05 (one-way ANOVA
followed by a post-hoc Student Newman-Keuls test was used to
determine differences in phosphorylated ERK1/2 activity).
doi:10.1371/journal.pone.0066067.g008
Shoc2 Structure-Function
PLOS ONE | www.plosone.org 9 June 2013 | Volume 8 | Issue 6 | e66067
.
Expression plasmids
Shoc2-tRFP, CFP-tagged Rab7 and Rab5 plasmids were
described previously [49,50]. The plasmid carrying YFP-Raf-1
was a gift from Dr. Sorkin (University of Pittsburgh). Truncated
Shoc2-tRFP tagged mutants were generated as described for the
full-length Shoc2 [27]. 3xHA-M-RAS plasmids were purchased
from Missouri S&T cDNA Resource Center (www.cdna.org). To
generate a plasmid stably expressing Shoc2 specific shRNA and
Shoc2-tRFP, the pLVTHM-Shoc2 construct and Shoc2-tRFP
construct resistant to shRNA knockdown were used (both were
described previously [27]. Shoc2-tRFP cDNA resistant to shRNA
knockdown containing PmeI and NdeI restriction sites was
synthesized. cDNA was ligated into pLVTHM-Shoc2 using PmeI
and NdeI restriction sites. The pLVTHM-Shoc2-Shoc2-tRFP
construct was verified by dideoxynucleotide sequencing.
Yeast two-hybrid (Y2H) screening
The full-length human Shoc2 was cloned into the lexA vector
pB27 as an N-LexA-Shoc2-C fusion and screened against a
human embryo ventricle and heart prey cDNA library. Y2H
screens were performed by Hybrigenics SA (http://www.
hybrigenics-services.com), Paris, France.
Sequence data and analysis
The reference for all complete Shoc2 sequences from vertebrate
and invertebrate species available on April 2012 were collected
from the NCBI Entrez Nucleotide database (http://www.ncbi.
nlm.nih.gov) using the Blastn and Blastp search algorithm
(Supporting Information S1) (Altschul et al., 1997). In our searches
of databases for Shoc2 orthologues, we used the criteria that Shoc2
orthologues must have a maximum percentile of sequence
similarity, a maximum number of LRRs and contain a non-
LRR amino-terminal region. Orthologues of each member of the
Shoc2 family were confirmed by a maximum likelihood tree using
the Geneious 5.7.5 software. Multiple alignments of the amino
acid sequences for the full lengths of each member were performed
using the Geneious 5.7.5 software, and then aligned sequences
were partitioned into LRR sequences based on LRRs consensus
sequences identified prior [31]. Alignments of the LRRs were also
checked by eye.
Molecular Modeling
A model of the Shoc2 LRR domain encompassing residues
101–560 was constructed. The N-terminal repeats (residues 101–
246) were modeled using A29 as a template (PDB=2O6Q) [51],
the middle repeats (residues 247–517) were modeled using BRI1 as
a template (PDB=3RGZ) [52], and the C-terminal repeats
(residues 518–578) were modeled using TLR4 as a template
(PDB=2Z64) [51]. The N- and middle repeats were generated
using the SWISS-MODEL automated prediction server [53] and
C-terminal repeats using the Phyer2 protein threading server [54].
A well-packed representative model containing all repeats
arranged in the expected LRR topology was constructed using
least squares fit [55] of overlapping regions. Figures were prepared
using MOLMOL [56].
Cell Culture and DNA Transfections
293FT cells (Invitrogen), Cos-1(ATCC), and stable cell lines
(Cos-LV1, LV-NT, LV-SR) (derivative of Cos-1 cells) were grown
in Dulbecco Modified Eagle’s Medium (DMEM) containing 10%
fetal bovine serum (FBS) supplemented with Sodium Pyruvate,
MEM-NEAA, Penicillin, Streptomycin, and L-Glutamate (Invi-
trogen). The transfections of DNA constructs were performed
using PEI (Neo Transduction Laboratories, Lexington, KY) or
TransITH (Mirus Bio LLC) reagents. Expression of tagRFP-fused
proteins was confirmed by Western blotting as described below.
Immunoprecipitation and Western blot analysis
The Cos1 and 293FT cells grown in 35-mm dishes were placed
on ice and washed with CMF-PBS, and the proteins were
solubilized in 20 mM HEPES (Sigma) pH 7.6, 10 mM NaCl,
1.5mM MgCl2, 1 mM EDTA (Sigma), 1 mM EGTA (Sigma),
0.5 mM PMSF (Sigma), 10 mg/ml of leupeptin (Roche), 10 mg/ml
of aprotinin (Roche), 5 mg/ml of pepstatin A (Sigma), 50 mM b-
glycerophosphate (Sigma) lysis buffer for 15 min at 4uC [57].
Lysates were then centrifuged at 2,5006g for 15 min to remove
the insoluble material. Lysates were incubated with appropriate
antibodies for 2 h, and the immuno-complexes were precipitated
using Protein A or G Sepharose. Immunoprecipitates and aliquots
of cell lysates were denatured in the sample buffer at 95uC,
resolved by electrophoresis, and probed by Western blotting with
various antibodies followed by the chemiluminescence detection.
Western blotting was done as described previously [58]. Glutathi-
one-S-transferase (GST) pull-down was done similarly to the
immunoprecipitation above, using glutathione-coupled beads for
purification of the immunocomplex. Several x-ray films were
analyzed to determine the linear range of the chemiluminescence
signals, and the quantifications were performed using the
densitometry analysis mode of the Image Lab software (Bio-Rad,
Inc). In all experiments, statistical analyses were performed with
one-way ANOVA followed by a post-hoc Student Newman-Keuls
test or with a nonparametric Kruskal-Wallis test when required.
These analyses were performed using SigmaStat3.5 (Systat
Software, Inc. Point Richmond, CA).
Fluorescence imaging of living cells
The cells were plated 24 hours before the experiment onto 35-
mm glass-bottom dishes and kept in serum free and phenol red
free medium containing 0.2% BSA for 16–20 hours. Cells grown
on glass-bottom dishes were either treated or not treated with
0.2 ng/ml of EGF. All images were acquired using a Mariannas
Imaging system consisting of a Zeiss inverted microscope equipped
with a cooled CCD CoolSnap HQ (Roper, CA), dual filter wheels
and a Xenon 175 W light source, all controlled by SlideBook 5.32
software (Intelligent Imaging Innovations, Denver, CO). The
detection of tagRFP fluorescence was performed using a TRIC
channel and CFP using a CFP channel. Images were acquired
using 262 binning mode. Image analysis was performed using the
SlideBook 5.32 software.
Nuclear–cytoplasmic fractionation
Cos-LV1 cells were transfected with plasmids expressing
different Shoc2 truncated fragments. After 48 hours of transfec-
tion, nuclear and cytosolic extracts were prepared using the NE-
PER Nuclear and Cytoplasmic Extraction Reagents kit (Thermo
Fisher Scientific) according to the manufacturer’s protocol. Briefly,
cells were washed once with cold PBS. Cells were collected by
centrifugation at 5006g for 5 min. The pellet was resuspended in
200 ml of CER I (cytoplasmic extraction reagent I) and incubated
on ice for 15 min. CER II (cytoplasmic extraction reagent II) was
added and samples were vortexed for 5 seconds. Nuclei were
collected by centrifugation at 10,0006g for 15 min at 4uC, and the
supernatant was transferred to a pre-chilled tube for cytosolic
fraction. The nuclei were then washed with cold PBS, centrifuged
and resuspended in 100 ml NER (nuclear extraction reagent),
incubated on ice for 15 min, and then centrifuged at 10,0006g for
10 min. Protein concentration was determined using Bio-Rad
Shoc2 Structure-Function
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Protein Assay reagent. P84 was used as a nuclear and GAPDH




Figure S1 Multiple alignment of the Shoc2 N-terminal
domain. An alignment of the N-terminal domains is to highlight
the conservation of amino residues in vertebrate spices. The
intensity of the background reflects the % of conservation of a
given position within the 10 sequences (light grey.60%, dark
grey.80%, black, full identity).
(PDF)
Figure S2 Full-length Shoc2-tRFP and Shoc2-tRFP trun-
cated mutants have differential protein half-life. A,
Schematic representation of the full-length and truncated Shoc2-
tRFP constructs. B, Cos1 cells were transiently transfected with
full-length Shoc2-tRFP or Shoc2-tRFP mutants. Thirty-six hours
post-transfection cells were treated with 30 mM Cycloheximide for
indicated times at 37uC. The lysates were probed by immuno-
blotting (IB) for tRFP, Cyclin D and GAPDH (loading control).
(PDF)
Figure S3 Shoc2 binding of Raf-1 in 293FT cells. A,
Schematic representation of the full-length and truncated Shoc2-
tRFP constructs. B, 293FT cells were transiently co-transfected
with expression vectors encoding full-length or truncated tagRFP-
tagged Shoc2 and GST-Raf-1. Thirty-six hours post-transfection,
cells were lysed. GST-Raf-1 was precipitated with glutathione-
coupled beads. The precipitated fraction was analyzed by
immuno-blotting (IB) with tRFP and subsequently with Raf-1 to
detect Raf-1. Cell lysates were immunoblotted with Raf-1
antibodies to monitor expression of GST-Raf-1, and tRFP
antibodies to monitor expression of Shoc2 and its corresponding
mutant used in panel IP.
(PDF)
Figure S4 Activation of the ERK1/2 pathway in Cos1,
Cos-LV1 and Cos-SR cells. Cos1, Cos-LV1, LV-SR, and Cos-
1 cells transiently transfected with tRFP for 36 h were treated with
EGF (0.2 ng/mL) for indicated times at 37uC. The lysates were
probed by immuno-blotting (IB) for pErk1/2, Shoc2, tRFP, and
total Erk1/2 (loading control).
(PDF)
Movie S1 Cos-LV1 cells were transiently transfected
with Shoc2-tRFP truncated mutants (aa532–582). Time-
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